Trial Profile
An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in Combination With Decitabine in Patients With Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs BI 836858 (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 26 Jan 2023 Status changed from active, no longer recruiting to completed.
- 04 Oct 2022 Planned End Date changed from 31 Dec 2022 to 19 Jan 2023.
- 04 Oct 2022 Planned primary completion date changed from 31 Dec 2022 to 19 Jan 2023.